skip to content
Nanoformulation d'une molécule antirétrovirale pour le ciblage des réservoirs du VIH-1 Preview this item
ClosePreview this item
Checking...

Nanoformulation d'une molécule antirétrovirale pour le ciblage des réservoirs du VIH-1

Author: Marion QuailletElias FattalHervé HillaireauAmélie BochotFlorence Gazeau, membre du jury d'une thèse de doctorat en immunologie).All authors
Publisher: 2018.
Dissertation: Thèse de doctorat : Pharmacotechnie et biopharmacie : Université Paris-Saclay (ComUE) : 2018.
Edition/Format:   Computer file : Document : Thesis/dissertation : French
Summary:
Bien que les multithérapies aient révolutionné le traitement de l'infection VIH, ces traitements échouent aujourd'hui encore à éradiquer le virus de l'organisme. En cause, la faible accessibilité des antirétroviraux à certains tissus, notamment lymphoïdes, empêche l'élimination du virus dans ces réservoirs de l'infection. C'est actuellement un des principaux freins aux interruptions thérapeutiques,
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Thèses et écrits académiques
Material Type: Document, Thesis/dissertation
Document Type: Computer File
All Authors / Contributors: Marion Quaillet; Elias Fattal; Hervé Hillaireau; Amélie Bochot; Florence Gazeau, membre du jury d'une thèse de doctorat en immunologie).; Véronique Préat; Ariane Boudier; Marie-Lise Gougeon; Pascale Kousignian; Université Paris-Saclay (2015-2019).; École doctorale Innovation thérapeutique : du fondamental à l'appliqué (Châtenay-Malabry, Hauts-de-Seine / 2015-....).; Institut Galien Paris-Saclay (Châtenay-Malabry, Hauts-de-Seine / 1998-....).; Université Paris-Sud (1970-2019).
OCLC Number: 1091190263
Notes: Titre provenant de l'écran-titre.
Description: 1 online resource
Responsibility: Marion Quaillet ; sous la direction de Elias Fattal et de Hervé Hillaireau.

Abstract:

Bien que les multithérapies aient révolutionné le traitement de l'infection VIH, ces traitements échouent aujourd'hui encore à éradiquer le virus de l'organisme. En cause, la faible accessibilité des antirétroviraux à certains tissus, notamment lymphoïdes, empêche l'élimination du virus dans ces réservoirs de l'infection. C'est actuellement un des principaux freins aux interruptions thérapeutiques, avec pour conséquence des traitements à vie pour les patients. Or les traitements actuels sont particulièrement contraignants pour le patient avec des prises multiples et quotidiennes d'antirétroviraux, ce qui limite leurs observances et leur qualité de vie.Au cours de cette thèse, des nanogels à base de chitosane ont été conçus et évalués au niveau cellulaire pour l'administration de l'enfuvirtide, un inhibiteur de fusion. La délivrance cellulaire de l'enfuvirtide a été modulée par les propriétés physico-chimiques des nanogels. Les nanogels ont également permis de maintenir l'activité antivirale de l'enfuvirtide sur les cellules infectées par le VIH. Quant aux études in vivo, elles ont montré le potentiel des nanogels pour cibler les ganglions lymphatiques, par voie sous-cutanée. De plus, les nanogels ont été incorporés dans un implant biodégradable à formation in situ. Après injection sous-cutanée, ces implants ont montré une libération prolongée sur plusieurs jours des nanogels.

Although highly active antiretroviral therapies (HAART) have significantly improved the HIV infection treatment, important hurdles remain towards an HIV cure. Due to their low bioavailability, penetration and/or residence time, antiretrovirals have restricted access to tissue compartments such as lymphoid tissue and latent HIV reservoirs. Reservoirs prevent the eradication of the virus and result in a lifelong treatment for HIV infected patients. Currently, compliance and the patient quality of life are limited by dose frequency.During this thesis, chitosan-based nanogels are developed and evaluated for the enfuvirtide delivery, an HIV-1 fusion inhibitor peptide. The cellular distribution of enfuvirtide delivered as nanogels show the combined effect of physicochemical properties in terms of particle size and surface charge. Nanogels also maintain the antiviral activity of enfuvirtide on HIV-infected cells. In vivo studies, after subcutaneous administration in mice, demonstrate the ability of nanogels to target lymph nodes. Furthermore, nanogels were incorporated in an in situ forming implant. After subcutaneous injection, the implant allows gradual release of nanogels over several days.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/1091190263<\/a>> # Nanoformulation d\'une mol\u00E9cule antir\u00E9trovirale pour le ciblage des r\u00E9servoirs du VIH-1<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:ComputerFile<\/a>, schema:CreativeWork<\/a>, schema:MediaObject<\/a>, bgn:Thesis<\/a> ;\u00A0\u00A0\u00A0\nbgn:inSupportOf<\/a> \"Th\u00E8se de doctorat : Pharmacotechnie et biopharmacie : Universit\u00E9 Paris-Saclay (ComUE) : 2018.<\/span>\" ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"1091190263<\/span>\" ;\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/id.loc.gov\/vocabulary\/countries\/fr<\/a>> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/ciblage_ganglionnaire<\/a>> ; # Ciblage ganglionnaire<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/chitosane<\/a>> ; # Chitosane<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/vih<\/a>> ; # Vih<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/reservoirs_viraux<\/a>> ; # R\u00E9servoirs viraux<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/nanovecteurs<\/a>> ; # Nanovecteurs<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/infections_a_vih<\/a>> ; # Infections \u00E0 VIH<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/nanogels<\/a>> ; # Nanogels<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/enfuvirtide<\/a>> ; # Enfuvirtide<\/span>\n\u00A0\u00A0\u00A0\nschema:author<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/quaillet_marion_1991<\/a>> ; # Marion Quaillet<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/ecole_doctorale_innovation_therapeutique_du_fondamental_a_l_applique_chatenay_malabry_hauts_de_seine_2015<\/a>> ; # \u00C9cole doctorale Innovation th\u00E9rapeutique : du fondamental \u00E0 l\'appliqu\u00E9 (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 2015-....).<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/kousignian_pascale<\/a>> ; # Pascale Kousignian<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/fattal_elias<\/a>> ; # Elias Fattal<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/preat_veronique<\/a>> ; # V\u00E9ronique Pr\u00E9at<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/universite_paris_saclay_2015_2019<\/a>> ; # Universit\u00E9 Paris-Saclay (2015-2019).<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/hillaireau_herve_1980<\/a>> ; # Herv\u00E9 Hillaireau<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/gougeon_marie_lise<\/a>> ; # Marie-Lise Gougeon<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/institut_galien_paris_saclay_chatenay_malabry_hauts_de_seine_1998<\/a>> ; # Institut Galien Paris-Saclay (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 1998-....).<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/gazeau_florence_19_membre_du_jury_d_une_these_de_doctorat_en_immunologie<\/a>> ; # membre du jury d\'une th\u00E8se de doctorat en immunologie). Florence Gazeau<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/bochot_amelie_1969<\/a>> ; # Am\u00E9lie Bochot<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/boudier_ariane_1981<\/a>> ; # Ariane Boudier<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/universite_paris_sud_1970_2019<\/a>> ; # Universit\u00E9 Paris-Sud (1970-2019).<\/span>\n\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2018<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"Bien que les multith\u00E9rapies aient r\u00E9volutionn\u00E9 le traitement de l\'infection VIH, ces traitements \u00E9chouent aujourd\'hui encore \u00E0 \u00E9radiquer le virus de l\'organisme. En cause, la faible accessibilit\u00E9 des antir\u00E9troviraux \u00E0 certains tissus, notamment lympho\u00EFdes, emp\u00EAche l\'\u00E9limination du virus dans ces r\u00E9servoirs de l\'infection. C\'est actuellement un des principaux freins aux interruptions th\u00E9rapeutiques, avec pour cons\u00E9quence des traitements \u00E0 vie pour les patients. Or les traitements actuels sont particuli\u00E8rement contraignants pour le patient avec des prises multiples et quotidiennes d\'antir\u00E9troviraux, ce qui limite leurs observances et leur qualit\u00E9 de vie.Au cours de cette th\u00E8se, des nanogels \u00E0 base de chitosane ont \u00E9t\u00E9 con\u00E7us et \u00E9valu\u00E9s au niveau cellulaire pour l\'administration de l\'enfuvirtide, un inhibiteur de fusion. La d\u00E9livrance cellulaire de l\'enfuvirtide a \u00E9t\u00E9 modul\u00E9e par les propri\u00E9t\u00E9s physico-chimiques des nanogels. Les nanogels ont \u00E9galement permis de maintenir l\'activit\u00E9 antivirale de l\'enfuvirtide sur les cellules infect\u00E9es par le VIH. Quant aux \u00E9tudes in vivo, elles ont montr\u00E9 le potentiel des nanogels pour cibler les ganglions lymphatiques, par voie sous-cutan\u00E9e. De plus, les nanogels ont \u00E9t\u00E9 incorpor\u00E9s dans un implant biod\u00E9gradable \u00E0 formation in situ. Apr\u00E8s injection sous-cutan\u00E9e, ces implants ont montr\u00E9 une lib\u00E9ration prolong\u00E9e sur plusieurs jours des nanogels.<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"Although highly active antiretroviral therapies (HAART) have significantly improved the HIV infection treatment, important hurdles remain towards an HIV cure. Due to their low bioavailability, penetration and\/or residence time, antiretrovirals have restricted access to tissue compartments such as lymphoid tissue and latent HIV reservoirs. Reservoirs prevent the eradication of the virus and result in a lifelong treatment for HIV infected patients. Currently, compliance and the patient quality of life are limited by dose frequency.During this thesis, chitosan-based nanogels are developed and evaluated for the enfuvirtide delivery, an HIV-1 fusion inhibitor peptide. The cellular distribution of enfuvirtide delivered as nanogels show the combined effect of physicochemical properties in terms of particle size and surface charge. Nanogels also maintain the antiviral activity of enfuvirtide on HIV-infected cells. In vivo studies, after subcutaneous administration in mice, demonstrate the ability of nanogels to target lymph nodes. Furthermore, nanogels were incorporated in an in situ forming implant. After subcutaneous injection, the implant allows gradual release of nanogels over several days.<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/9001229896<\/a>> ;\u00A0\u00A0\u00A0\nschema:genre<\/a> \"Th\u00E8ses et \u00E9crits acad\u00E9miques<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\nschema:inLanguage<\/a> \"fr<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Nanoformulation d\'une mol\u00E9cule antir\u00E9trovirale pour le ciblage des r\u00E9servoirs du VIH-1<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"1091190263<\/span>\" ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/1091190263<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/ecole_doctorale_innovation_therapeutique_du_fondamental_a_l_applique_chatenay_malabry_hauts_de_seine_2015<\/a>> # \u00C9cole doctorale Innovation th\u00E9rapeutique : du fondamental \u00E0 l\'appliqu\u00E9 (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 2015-....).<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"\u00C9cole doctorale Innovation th\u00E9rapeutique : du fondamental \u00E0 l\'appliqu\u00E9 (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 2015-....).<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/institut_galien_paris_saclay_chatenay_malabry_hauts_de_seine_1998<\/a>> # Institut Galien Paris-Saclay (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 1998-....).<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Institut Galien Paris-Saclay (Ch\u00E2tenay-Malabry, Hauts-de-Seine \/ 1998-....).<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/universite_paris_saclay_2015_2019<\/a>> # Universit\u00E9 Paris-Saclay (2015-2019).<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Universit\u00E9 Paris-Saclay (2015-2019).<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Organization\/universite_paris_sud_1970_2019<\/a>> # Universit\u00E9 Paris-Sud (1970-2019).<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Universit\u00E9 Paris-Sud (1970-2019).<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/bochot_amelie_1969<\/a>> # Am\u00E9lie Bochot<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:birthDate<\/a> \"1969<\/span>\" ;\u00A0\u00A0\u00A0\nschema:deathDate<\/a> \"\" ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Bochot<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Am\u00E9lie<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Am\u00E9lie Bochot<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/boudier_ariane_1981<\/a>> # Ariane Boudier<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:birthDate<\/a> \"1981<\/span>\" ;\u00A0\u00A0\u00A0\nschema:deathDate<\/a> \"\" ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Boudier<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Ariane<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Ariane Boudier<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/fattal_elias<\/a>> # Elias Fattal<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Fattal<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Elias<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Elias Fattal<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/gazeau_florence_19_membre_du_jury_d_une_these_de_doctorat_en_immunologie<\/a>> # membre du jury d\'une th\u00E8se de doctorat en immunologie). Florence Gazeau<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:birthDate<\/a> \"19..<\/span>\" ;\u00A0\u00A0\u00A0\nschema:deathDate<\/a> \";<\/span>\" ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Gazeau<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Florence<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"membre du jury d\'une th\u00E8se de doctorat en immunologie). Florence Gazeau<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/gougeon_marie_lise<\/a>> # Marie-Lise Gougeon<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Gougeon<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Marie-Lise<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Marie-Lise Gougeon<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/hillaireau_herve_1980<\/a>> # Herv\u00E9 Hillaireau<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:birthDate<\/a> \"1980<\/span>\" ;\u00A0\u00A0\u00A0\nschema:deathDate<\/a> \"\" ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Hillaireau<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Herv\u00E9<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Herv\u00E9 Hillaireau<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/kousignian_pascale<\/a>> # Pascale Kousignian<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Kousignian<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Pascale<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Pascale Kousignian<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/preat_veronique<\/a>> # V\u00E9ronique Pr\u00E9at<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Pr\u00E9at<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"V\u00E9ronique<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"V\u00E9ronique Pr\u00E9at<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Person\/quaillet_marion_1991<\/a>> # Marion Quaillet<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:birthDate<\/a> \"1991<\/span>\" ;\u00A0\u00A0\u00A0\nschema:deathDate<\/a> \"\" ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Quaillet<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Marion<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Marion Quaillet<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/ciblage_ganglionnaire<\/a>> # Ciblage ganglionnaire<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Ciblage ganglionnaire<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/nanovecteurs<\/a>> # Nanovecteurs<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Nanovecteurs<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/reservoirs_viraux<\/a>> # R\u00E9servoirs viraux<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"R\u00E9servoirs viraux<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Thing\/vih<\/a>> # Vih<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Vih<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/chitosane<\/a>> # Chitosane<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Chitosane<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/enfuvirtide<\/a>> # Enfuvirtide<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Enfuvirtide<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/infections_a_vih<\/a>> # Infections \u00E0 VIH<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Infections \u00E0 VIH<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/9001229896#Topic\/nanogels<\/a>> # Nanogels<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Nanogels<\/span>\"@fr<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/vocabulary\/countries\/fr<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\ndcterms:identifier<\/a> \"fr<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/1091190263<\/a>>\u00A0\u00A0\u00A0\u00A0a \ngenont:InformationResource<\/a>, genont:ContentTypeGenericResource<\/a> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/www.worldcat.org\/oclc\/1091190263<\/a>> ; # Nanoformulation d\'une mol\u00E9cule antir\u00E9trovirale pour le ciblage des r\u00E9servoirs du VIH-1<\/span>\n\u00A0\u00A0\u00A0\nschema:dateModified<\/a> \"2020-10-12<\/span>\" ;\u00A0\u00A0\u00A0\nvoid:inDataset<\/a> <http:\/\/purl.oclc.org\/dataset\/WorldCat<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Content-negotiable representations<\/p>\n